AAAAAA

   
Results: 1-11 |
Results: 11
Vancomycin-intermediate Staphylococcus aureus in a home health-care patient
Authors: Hageman, JC Pegues, DA Jepson, C Bell, RL Guinan, M Ward, KW Cohen, MD Hindler, JA Tenover, FC McAllister, SK Kellum, ME Fridkin, SK
Citation: Jc. Hageman et al., Vancomycin-intermediate Staphylococcus aureus in a home health-care patient, EM INFECT D, 7(6), 2001, pp. 1023-1025
SB-239063, a potent and selective inhibitor of p38 map kinase: Preclinicalpharmacokinetics and species-specific reversible isomerization
Authors: Ward, KW Proksch, JW Azzarano, LM Salyers, KL McSurdy-Freed, JE Molnar, TM Levy, MA Smith, BR
Citation: Kw. Ward et al., SB-239063, a potent and selective inhibitor of p38 map kinase: Preclinicalpharmacokinetics and species-specific reversible isomerization, PHARM RES, 18(9), 2001, pp. 1336-1344
Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience
Authors: Marlowe, EM Cohen, MD Hindler, JF Ward, KW Bruckner, DA
Citation: Em. Marlowe et al., Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience, J CLIN MICR, 39(7), 2001, pp. 2637-2639
Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics
Authors: Ward, KW Proksch, JW Levy, MA Smith, BR
Citation: Kw. Ward et al., Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics, DRUG META D, 29(1), 2001, pp. 82-88
Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase
Authors: Ward, KW Proksch, JW Azzarano, LM Mumaw, JA Roethke, TJ Stelman, GJ Walsh, MJ Zeigler, KS McSurdy-Freed, JE Kehler, JR Chokshi, J Levy, MA Smith, BR
Citation: Kw. Ward et al., Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase, XENOBIOTICA, 31(11), 2001, pp. 783-797
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models
Authors: Ames, RS Lee, D Foley, JJ Jurewicz, AJ Tornetta, MA Bautsch, W Settmacher, B Klos, A Erhard, KF Cousins, RD Sulpizio, AC Hieble, JP McCafferty, G Ward, KW Adams, JL Bondinell, WE Underwood, DC Osborn, RR Badger, AM Sarau, HM
Citation: Rs. Ames et al., Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models, J IMMUNOL, 166(10), 2001, pp. 6341-6348
Comparative pathogenesis of haloacetic acid and protein kinase inhibitor embryotoxicity in mouse whole embryo culture
Authors: Ward, KW Rogers, EH Hunter, ES
Citation: Kw. Ward et al., Comparative pathogenesis of haloacetic acid and protein kinase inhibitor embryotoxicity in mouse whole embryo culture, TOXICOL SCI, 53(1), 2000, pp. 118-126
Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity
Authors: Ward, KW Griffiths, R Levy, MA Smith, BR
Citation: Kw. Ward et al., Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity, J PHARM EXP, 293(2), 2000, pp. 468-479
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
Authors: Miller, WH Alberts, DP Bhatnagar, PK Bondinell, WE Callahan, JF Calvo, RR Cousins, RD Erhard, KF Heerding, DA Keenan, RM Kwon, C Manley, PJ Newlander, KA Ross, ST Samanen, JM Uzinskas, IN Venslavsky, JW Yuan, CCK Haltiwanger, RC Gowen, M Hwang, SM James, IE Lark, MW Rieman, DJ Stroup, GB Azzarano, LM Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic, J MED CHEM, 43(1), 2000, pp. 22-26
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
Authors: Miller, WH Bondinell, WE Cousins, RD Erhard, KF Jakas, DR Keenan, RM Ku, TW Newlander, KA Ross, ST Haltiwanger, RC Bradbeer, J Drake, FH Gowen, M Hoffman, SJ Hwang, SM James, IE Lark, MW Lechowska, B Rieman, DJ Stroup, GB Vasko-Moser, JA Zembryki, DL Azzarano, LM Adams, PC Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model, BIOORG MED, 9(13), 1999, pp. 1807-1812
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist
Authors: Ward, KW Azzarano, LM Bondinell, WE Cousins, RD Huffman, WF Jakas, DR Keenan, RM Ku, TW Lundberg, D Miller, WH Mumaw, JA Newlander, KA Pirhalla, JL Roethke, TJ Salyers, KL Souder, PR Stelman, GJ Smith, BR
Citation: Kw. Ward et al., Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist, DRUG META D, 27(11), 1999, pp. 1232-1241
Risultati: 1-11 |